This slideshow examines regorafenib (Stivarga), indicated for the treatment of patients with metastatic colorectal cancer (CRC) or metastatic gastrointestinal stromal tumor (GIST) . Table of Contents Slide 4: Indication, Dosage, and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 27: References
This slideshow examines atezolizumab (Tecentriq), indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
This slideshow examines cabozantinib (Cabometyx), indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
This slideshow reviews venetoclax (Venclexta), indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least 1 prior therapy.
This slideshow reviews necitumumab (Portrazza), indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC), in combination with gemcitabine and cisplatin.
This slideshow reviews daratumumab (Darzalex), indicated for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or who are double-refractory to a PI and an IMiD.
This slideshow reviews elotuzumab (Empliciti), indicated for the treatment of patients with multiple myeloma who have received 1 to 3 prior therapies, in combination with lenalidomide and dexamethasone.
This slideshow reviews uridine alectinib (Alecensa), indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This slideshow reviews uridine triacetate (Vistogard), indicated for the emergency treatment of patients following a fluorouracil (5-FU) or capecitabine overdose, or in cases of early onset, severe, or life-threatening toxicity affecting the cardiac or central nervous system, and/or early onset, unusually severe adverse reactions within 96 hours after 5-FU or capecitabine administration.
This slideshow reviews cobimetinib (Cotellic), indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
